By Denny Jacob

Eli Lilly's Jaypirca was approved by the Food and Drug Administration to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.

The Indianapolis-based pharmaceutical company said Friday that Jaypirca was approved under the FDA's accelerated approval pathway based on results from a trial.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 01, 2023 17:51 ET (22:51 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Eli Lilly Charts.